Skip to main content

Table 2 List of METTL3 modulators

From: N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

Type Function Name/Company IC50/EC50 Cancer Estimated phase I trial start date References
Activator Specific activator Compound 3 117 nM ND ND [121]
Inhibitor Pan-MTase inhibitor Sinefungin 2.36μΜ ND ND [121]
3-deazaadenosine ND ND ND [129]
Specific inhibitor Compound 2 8.7 μM ND ND [126]
UZH1a 280 nM AML ND [127]
STM2457/STORM Therapeutics 16.9 nM AML 2021 [128]
Accent Therapeutics ND AML, NSCLC 2021, 2022 [120]
  1. AML acute myeloid leukemia, NSCLC non-small cell lung cancer, ND no data available